Literature DB >> 16896670

Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma.

Yoshihiro Nishiyama1, Yuka Yamamoto, Toshihide Monden, Yasuhiro Sasakawa, Nobuyuki Kawai, Katashi Satoh, Motoomi Ohkawa.   

Abstract

PURPOSE: The purpose of this study was to investigate the accumulation of FDG in immunocompetent patients with primary central nervous system (CNS) lymphoma using qualitative and quantitative PET images and to compare baseline with follow-up PET after therapy.
METHODS: Twelve immunocompetent patients with CNS lymphoma were examined. Dynamic emission data were acquired for 60 min immediately following injection of FDG. In seven patients, repeated PET studies were performed after treatment. Applying a three-compartment five-parameter model, K (1), k (2), k (3), k (4), vascular fraction (V ( B )) and cerebral metabolic rate of glucose (CMR(Glc)) were obtained. We evaluated the FDG uptake visually using qualitative and parametric images and quantitatively using parametric images.
RESULTS: A total of 12 lesions were identified in ten patients with newly diagnosed CNS lymphoma. On visual analysis, ten lesions showed an increase on qualitative images, eight showed an increase on K (1) images, 12 showed an increase on k (3) images and ten showed an increase on CMR(Glc) images. On quantitative analysis, k (2), k (3) and CMR(Glc) values of the lesion were significantly different from those of the normal grey matter (p<0.02-0.0005). A total of three lesions were identified in two patients with recurrent tumour. All three lesions showed an increase on qualitative, k (3) and CMR(Glc) images. The K (1), k (2), k (3) and CMR(Glc) values after treatment were significantly different from those obtained before treatment (p<0.04-0.008).
CONCLUSION: Kinetic analysis, especially with respect to k (3), using dynamic FDG PET might be helpful for diagnosis of CNS lymphoma and for monitoring therapeutic assessment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896670     DOI: 10.1007/s00259-006-0153-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

1.  FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.

Authors:  H Palmedo; H Urbach; H Bender; U Schlegel; I G H Schmidt-Wolf; A Matthies; M Linnebank; A Joe; J Bucerius; H-J Biersack; H Pels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-12       Impact factor: 9.236

2.  FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS.

Authors:  J M Hoffman; H A Waskin; T Schifter; M W Hanson; L Gray; S Rosenfeld; R E Coleman
Journal:  J Nucl Med       Date:  1993-04       Impact factor: 10.057

3.  FDG transport and phosphorylation in human gliomas measured with dynamic PET.

Authors:  K Herholz; J Rudolf; W D Heiss
Journal:  J Neurooncol       Date:  1992-02       Impact factor: 4.130

4.  Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

Authors:  David A Mankoff; Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Aaron Charlop; Thomas J Lawton; Erin K Schubert; Jeffrey Tseng; Robert B Livingston
Journal:  J Nucl Med       Date:  2002-04       Impact factor: 10.057

5.  Glucose consumption and rate constants for 18F-fluorodeoxyglucose in human gliomas.

Authors:  M Ishikawa; H Kikuchi; I Nagata; S Yamagata; W Taki; Y Yonekura; S Nishizawa; Y Iwasaki; T Mukai
Journal:  Neurol Med Chir (Tokyo)       Date:  1990-06       Impact factor: 1.742

6.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.

Authors:  R L Wahl; K Zasadny; M Helvie; G D Hutchins; B Weber; R Cody
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

Review 7.  Primary brain tumours in adults.

Authors:  Anthony Behin; Khe Hoang-Xuan; Antoine F Carpentier; Jean-Yves Delattre
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

Review 8.  Primary central nervous system lymphoma.

Authors:  F H Hochberg; D C Miller
Journal:  J Neurosurg       Date:  1988-06       Impact factor: 5.115

9.  Comparative regional analysis of 2-fluorodeoxyglucose and methylglucose uptake in brain of four stroke patients. With special reference to the regional estimation of the lumped constant.

Authors:  A Gjedde; K Wienhard; W D Heiss; G Kloster; N H Diemer; K Herholz; G Pawlik
Journal:  J Cereb Blood Flow Metab       Date:  1985-06       Impact factor: 6.200

10.  Measurement of glucose and 2-deoxy-2-[18F]fluoro-D-glucose transport and phosphorylation rates in myocardium using dual-tracer kinetic experiments.

Authors:  S C Huang; B A Williams; J R Barrio; J Krivokapich; C Nissenson; E J Hoffman; M E Phelps
Journal:  FEBS Lett       Date:  1987-05-25       Impact factor: 4.124

View more
  15 in total

1.  Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma.

Authors:  Yoshiro Kawase; Yuka Yamamoto; Reiko Kameyama; Nobuyuki Kawai; Nobuyuki Kudomi; Yoshihiro Nishiyama
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

2.  Patlak image estimation from dual time-point list-mode PET data.

Authors:  Wentao Zhu; Quanzheng Li; Bing Bai; Peter S Conti; Richard M Leahy
Journal:  IEEE Trans Med Imaging       Date:  2014-04       Impact factor: 10.048

3.  18F-FDG PET/CT in primary brain lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Mattia Bertoli; Raffaele Giubbini; Francesco Bertagna
Journal:  J Neurooncol       Date:  2017-11-17       Impact factor: 4.130

4.  Shortening the duration of [18F]FDG PET brain examination for diagnosis of brain glioma.

Authors:  Toshihide Monden; Nobuyuki Kudomi; Yasuhiro Sasakawa; Yuka Yamamoto; Nobuyuki Kawai; Yoshihiro Nishiyama
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

5.  Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment.

Authors:  Nobuyuki Kawai; Hai-Ning Zhen; Keisuke Miyake; Yuka Yamamaoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  J Neurooncol       Date:  2010-11       Impact factor: 4.130

6.  Cerebral Toxoplasmosis in a Patient with AIDS on F-18 FDG PET/CT.

Authors:  Hae Won Kim; Kyoung Sook Won; Byung Wook Choi; Seok Kil Zeon
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

7.  Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas.

Authors:  Yoshinobu Takahashi; Toshiaki Akahane; Daisuke Yamamoto; Hideo Nakamura; Hiroki Sawa; Kazumi Nitta; Wataru Ide; Ikuo Hashimoto; Hajime Kamada
Journal:  Mol Clin Oncol       Date:  2014-05-05

8.  Brain and whole-body FDG-PET in diagnosis, treatment monitoring and long-term follow-up of primary CNS lymphoma.

Authors:  Sofiane Maza; Ralph Buchert; Winfried Brenner; Dieter Ludwig Munz; Eckhard Thiel; Agnieszka Korfel; Philipp Kiewe
Journal:  Radiol Oncol       Date:  2013-05-21       Impact factor: 2.991

9.  Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review.

Authors:  Simone Krebs; Julia G Barasch; Robert J Young; Christian Grommes; Heiko Schöder
Journal:  Ann Lymphoma       Date:  2021-06-30

10.  The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology.

Authors:  Mustafa Takesh
Journal:  ISRN Oncol       Date:  2012-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.